Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.
Satoshi Yuki
No relevant relationships to disclose
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Hiraku Fukushima
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Toraji Amano
No relevant relationships to disclose
Takuto Miyagishima
No relevant relationships to disclose
Kazuteru Hatanaka
No relevant relationships to disclose
Michio Nakamura
No relevant relationships to disclose
Miki Tateyama
No relevant relationships to disclose
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Honsha